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Introduction
Th e purpose of Global Arthritis Research Network 
(GARN) is to promote and encourage scientifi c inter-
actions and collaborations that facilitate the progress of 
basic and clinical research in arthritis and related 
conditions. Last October, the 7th meeting of GARN was 
held in Zurich, Switzerland. Th e program – organized by 
Steff en Gay and Peter E Lipsky, associate editor and 
editor-in-chief, respectively, of Arthritis Research & 
Th erapy – was designed to provide the attendees with the 
newest insights into molecular biology related to 
musculo skeletal diseases. Th e opening session, entitled 
‘Genetics – epigenetics – proteomics’, was followed by 
sessions on ‘Signaling pathways’, ‘Molecular immunology’, 
‘Cellular autoimmunity’, and ‘Cell biology’. Th e fi nal 
session, on ‘Updates in rheumatology’, ended with an out-
look on novel modulators of pain. During the breaks and 
social gatherings, students and young fellows had the 
opportunity to ask questions and discuss the novel 
aspects of advanced technologies in molecular research. 
Fellows from the Center of Experimental Rheumatology 
at the Department of Rheumatology at the University 
Hospital in Zurich prepared notes from each session.
Session 1: Genetics – epigenetics – proteomics 
(part 1)
Chairs: Ravinder N Maini, London, UK, 
and Astrid Jüngel, Zurich, Switzerland
Session 1, part 1 summarized by Matthias Brock
Novel genotyping technologies
Ioannis Ragoussis, Oxford, UK
Dr. Ioannis Ragoussis’s presentation focused on novel 
genotyping technologies for the identifi cation of disease-
associated changes in DNA sequences. He began his talk 
by giving an overview of the role of single nucleotide 
polymor ph isms in human diseases and the currently 
available DNA sequencing platforms. Since the analysis 
of a larger number of patients is hindered by limitations 
of currently available technologies, Dr. Ragoussis pre-
sented a new sequencing platform. Th is novel genotyping 
tech nology is based on an Aff ymetrix genotyping array 
(Aff ymetrix, Santa Clara, CA, USA) combined with DNA 
ligation steps allowing the sequencing of a large number 
of samples. To illustrate this improved sequencing 
method, Dr. Ragoussis presented data from his lab, 
showing newly identifi ed copy number variation events 
in patients with autism. In the last part of his talk, he 
discussed the interesting fi eld of transcriptome analysis. 
He explained that RNA quantifi cation by sequencing 
combined with chromatin immunoprecipitation off ers a 
powerful new tool for studying the regulation of gene 
expression. He also mentioned how microRNA (miRNA) 
quantifi cation studies followed by RNA transcriptome 
analysis (miRNA-RNA Seq) could be used to understand 
the widespread eff ect of miRNAs on the RNA 
transcriptome.
Single-gene genetic analysis
Ernst Hafen, Zurich, Switzerland
In his talk, Dr. Ernst Hafen turned to the question of how 
cell, organ, and body size is genetically controlled. He 
explained that understanding the mecha nisms that 
control organismal size is of fundamental biological and 
clinical importance. By per forming genetic screens that 
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allow a randomized intro duction of mutations into the 
genome of Drosophila melanogaster, his lab was able to 
identify novel genes associated with body size. In 
summary, the investigators found approximately 60 genes 
that promoted or inhibited growth. Th e majority of these 
genes encode proteins that are part of the insulin/TOR 
signaling pathway. Further more, they could show that the 
activity of this pathway infl uences the cellular and 
organismal growth of Droso phila fl ies. In future projects, 
his group will perform large proteomic approaches to 
further characterize the function of these genes asso-
ciated with body size. In the last part of his talk, Dr. 
Hafen discussed the infl uence of environmental condi-
tions on growth and survival. He illustrated the role of 
the tumor suppressor Pten in caloric restriction (CR). 
Th e reduction of Pten activity, as he explained, is 
suffi  cient to compensate impaired insulin signaling and 
thus represents a growth advantage under starvation. To 
understand the complex role of Pten activity in 
organismal growth, his lab will employ a combi nation of 
single-gene analysis with quantitative measurement of 
protein levels (mass spectrometry).
Functional analysis of mammalian genomes
Joel Schick, Munich, Germany
Dr. Joel Schick began his presentation with the statement 
that human and mouse genomes are highly conserved 
and comprise approximately 20,000 coding genes. Th is 
high degree of similarity between the human and murine 
genomes can be used to study human diseases in mice. In 
this regard, the detailed characterization of each murine 
gene and its function is essential. A powerful tool for 
studying gene function is the specifi c silencing of genes 
(knockout) by applying conditional gene-trapping and 
gene-targeting methods. Th e goal of Dr. Schick’s group 
and their partners (in the European Conditional Mouse 
Mutagenesis Program) is to generate a collection of up to 
13,000 mutated genes in mouse embryonic stem cells. 
Th is library will enable mouse mutants to be established 
worldwide in a standardized and cost-eff ective manner, 
making mouse mutants available to a much wider 
biomedical research community. In his talk, Dr. Schick 
explained diff erent methods for knocking out gene 
expression in mouse embryonic cells. For instance, he 
mentioned gene trap vectors, a class of promoter-less 
reporter gene cassettes that integrate randomly into a 
large collection of chromosomal sites. It has been shown 
that gene trap mutagenesis is the method of choice for 
large-scale, genome-wide mutagenesis. Furthermore, Dr. 
Schick illustrated the use of the so-called Cre-Lox recom-
bi nation system to generate a conditional knockout 
animal; in this system, a gene is knocked out only in a 
specifi c tissue or at a specifi c time. Cre-Lox recom bi-
nation involves the targeting of a specifi c sequence of 
DNA and splicing it with the help of an enzyme called 
Cre recombinase. At the end of his talk, Dr. Schick 
mentioned established repositories for the collection and 
distribution of relevant mutant strains essential for basic 
biomedical research.
Session 1: Genetics – epigenetics – proteomics 
(part 2)
Chairs: David Pisetsky, Durham, NC, USA, 
and Caroline Ospelt, Zurich, Switzerland
Session 1, part 2 summarized by Michelle Trenkmann
Aggregating proteins
Adriano Aguzzi, Zurich, Switzerland
Are prions and prionoids a more common underlying 
principle of human diseases than appreciated until now? 
In the fi rst part of his presentation, Adriano Aguzzi 
raised the question of whether not only the ‘bona fi de’ 
prion disease caused by the prion particle PrPSc but also 
other disorders such as Alzheimer’s disease or AA 
amyloi dosis should be considered prion diseases. Th e 
pathobiological background of this view is the following: 
a protein can exist in two states: the normal state and the 
misfolded prion state. A pathogenic event initiates an 
assembly of misfolded proteins into aggregates, thus 
leading to the progressive neurologic degeneration seen 
in patients. PrPSc is transmissible and follows an 
infectious life cycle; that is, it acts as a seed to recruit 
more PrPSc. Diseases such as Alzheimer’s disease or AA 
amyloidosis have a similar pathogenesis and are caused 
by the deposition of misfolded proteins (amyloid-β and 
amyloid A, respectively). Aguzzi attested that AA amy-
loidosis has the ‘best chances’ of becoming a prion 
disease. He pointed out that prions may even have con-
served ‘good’ properties that may be the reason that 
prion formation was not simply eliminated by evolution. 
In the second part of the presentation, Aguzzi concen-
trated on his own group’s recent work, which deals with 
the question of how to study the neurotoxicity of PrPSc. 
Th ey developed an ex vivo assay using mouse cerebrellar 
slices that could be cultured for several weeks and in-
fected with prions. In the slices, as in the living animal, 
prion infection induced neurodegeneration. Th is tech-
nique allows investigators to address neurotoxicity ques-
tions that are diffi  cult to study in vivo. With this model, 
diff erent substances were tested for their neuroprotective 
activity, and work on how prion degradation could be 
infl uenced is ongoing.
Novel targeting with DARPins
Andreas Plückthun, Zurich, Switzerland
Andreas Plückthun started his presentation with the 
question ‘Antibodies in infl ammatory diseases: is it all 
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done?’ – to which he answered ‘no’, pointing out that 
approxi mately 30% of the patients do not respond to anti-
tumor necrosis factor (anti-TNF) treatment. Further more, 
opportunistic infections and enormous costs are 
common problems of biological treatments of today. 
After providing a short historical overview ranging from 
the fi rst monoclonal antibodies to recombinant anti-
bodies and synthetic antibodies, he concentrated on a 
class of molecules – called DARPins (designed ankyrin 
repeat proteins) – that may substitute antibodies. Th ese 
molecules are assembled from a variable number of 
ankyrin repeat domains that contain several randomized 
positions, making it possible to generate libraries of 
DARPins with a multitude of diff erent binding surfaces. 
Th eir unique properties – namely these molecules are 
extremely well expressed, soluble, stable, and non-
aggregating – and the possibility of carrying out the 
whole selection process in vitro by ribosomal display 
make them highly interesting for therapeutic approaches 
and research. Discussing the potential use of DARPins in 
therapy, Plückthun summarized work done to achieve 
high stability, affi  nity, and the ability to penetrate cells. 
Furthermore, he introduced a new concept of targeted 
gene therapy which is in development at the moment. In 
this therapy, adenoviruses carrying the therapeutic 
nucleic acid ‘fi nd’ their particular target cells with the 
help of a specifi cally selected DARPin adapter. Finally, 
coming to applications in research, he pointed out the 
limitations of using DARPins in proteomics and systems 
biology and briefl y introduced a new approach for 
designing modular peptide-binding scaff olds with the 
vision of achieving peptide recognition with predesigned 
building blocks of engineered Armadillo repeat proteins.
Modifi cation of histones
Udo Oppermann, Oxford, UK
To begin with, Udo Oppermann gave some background 
information on nucleosome structure and histone modi-
fi  cations and their relevance to the immune system. He 
continued with the presentation of the Structural 
Genomics Consortium (SGC), a public-private partner-
ship that aims to place protein structures of relevance to 
human health into the public domain and thus to 
promote drug discovery. Based on the SGC, the Chemical 
Probe Consortium works on the development of probes 
against specifi c biological targets which are then made 
available to the public. To concentrate on some of the 
possible 400 epigenetic targets, they chose bromo and 
tudor domains, which ‘read’ acetyl and methyl marks, 
respectively, and lysine demethylases. He presented 
recent progress on two targets in particular. One work 
was concerned with the development of a small-molecule 
competitor of the bromodomain BRD4, which is of 
interest for immunologic research since it binds to 
acety lated nuclear factor-kappa-B (NF-κB) and thus 
functions as a coactivator. Th e second work dealt with the 
search for small-molecule inhibitors of Jumonji proteins 
(lysine demethylases for histones and other non-histone 
proteins). For this, they started from α-ketoglutarate, a co-
substrate for the demethylation process. In the end, they 
came up with a specifi c inhibitor of Jmjd3, a lysine 
demethylase that has already been implicated in immune-
related processes. Oppermann stated the prospect that the 
molecule would be publicly available in the future as soon 
as it has been validated in a cell-based system.
DNA methylation alterations and autoimmune diseases
Esteban Ballestar, Barcelona, Spain
DNA methylation is the most common epigenetic 
modifi cation and involves the 5’-methylation of cytosine 
in CG dinucleotides that usually reside in so-called CpG 
islands. Esteban Ballestar spoke about aberrant DNA 
methylation found in diseases ranging from cancer to 
genetic defects concerning epigenetic factors (for example, 
Rett syndrome or ICF [immunodefi ciency, centromeric 
region instability, and facial anomalies] syndrome) and 
imprinting disorders such as Angelman and Prader-Willi 
syndromes. He pointed out that under normal condi tions 
DNA methylation plays an important role in X chromo-
some inactivation, imprinting, and the regulation of 
tissue-specifi c gene expression. Th erefore, promoter CpG 
islands tend to be demethylated whereas DNA repeat 
regions are normally methylated. In the diseased state, 
this seems to be reversed to a certain degree. Although 
cancer cells show a global hypomethylation, specifi c gene 
promoters, mainly those of tumor suppres sor and DNA 
repair genes, show a local hypermethylation that leads to 
the silencing of these genes. Ballestar concluded that, 
also in autoimmune diseases, epigenetic infl uences are 
indicated. Having a special interest in epigenetic diff er-
ences between monozygotic (MZ) twins, in whom global 
epigenetic diff erences were shown to accumulate with 
age, his group generated DNA methy lation profi les of 
MZ twins discordant for autoimmune diseases such as 
systemic lupus erythematosus (SLE), rheumatoid arthritis 
(RA), and dermatomyositis. Signifi  cant diff erences could 
be detected only for SLE discor dance, and many of the 
aff ected genes had an immuno logic function and were of 
relevance in lupus patho genesis. Hypomethylation of 
several genes was validated by bisulfi te pyrosequencing 
(for example, IFNGR2 and MMP14). In contrast, DNA 
methylation of repetitive sequences such as LINE1 or Alu 
repeats was not aff ected. Finally, he put forward the idea 
that there may be an active demethylation of 
pathogenetically relevant genes in lupus. In the end, 
Ballestar presented a second study demonstrating an 
association between Epstein-Barr virus infection and 
DNA methylation in B cells.
Brock et al. Arthritis Research & Therapy 2011, 13:303 
http://arthritis-research.com/content/13/4/303
Page 3 of 10
Session 2: Signaling pathways
Chairs: Joachim Kalden, Erlangen, Germany, 
and Gyorgy Nagy, Budapest, Hungary
Session 2 summarized by Maria Filkova
The infl ammasome
Jürg Tschopp, Epalinges, Switzerland
At the beginning of his talk, Dr. Tschopp introduced the 
infl ammasomes as cytosolic multiprotein complexes that 
can proteolytically activate caspase-1 and this subse-
quently leads to maturation and secretion of active inter-
leukin IL-1β and IL-18. Th e innate immune system is 
characterized by its ability to recognize a wide range of 
pathogen-associated molecular patterns (PAMPs) (such 
as fungi, protozoa, bacteria, or viruses) and sterile 
danger-associated molecular patterns (DAMPS) (such as 
DNA, ATP, crystals, asbestos, β amyloid, and choles terol). 
PAMPs are recognized by pattern-recognition receptors 
that include the Toll-like receptors, NOD-like receptors 
(NLRs), C-type lectin receptors, and several other recep-
tors. However, NLR proteins can also detect DAMPs and 
their recognition leads to the activation of the infl am ma-
some. NLR-related pathways (NALP or NLRP, IPAF, and 
AIM2) are associated with chronic non-infectious in-
fl am matory diseases. Dr. Tschopp presented the role of 
the infl ammasome in the pathogenesis of several chronic 
infl ammatory conditions.
Gout is associated with the deposition of monosodium 
urate (MSU) crystals. It was shown that molecular 
mecha nisms underlying the infl ammation initiated by 
MSU activate the NALP3 infl ammasome. Th e involve-
ment of IL-1β in this infl ammatory cascade might explain 
the success of IL-1ra, IL-1Trap, and IL-1β antibody 
treatment in gout infl ammation.
NALP3 infl ammasome is implicated in the patho-
genesis of another chronic infl ammatory state: type 2 
diabetes mellitus (DMT2). Reactive oxygen species (ROS) 
generation is necessary for NALP3 activation in DMT2. 
Moreover, when intracellular ROS increases, thioredoxin-
interacting protein (TXNIP) is released from the 
thioredoxin complex. Th e oxidoreductase thioredoxin is 
then able to act as an ROS scavenger and then free 
TXNIP interacts with NALP3. Th us, TXNIP is a ligand 
for NLRP3, leading to elevated IL-1β production. IL-1β 
has a pathogenic role in islet dysfunction and is a risk 
factor for the development of DMT2 in humans. Mouse 
models and human clinical trials suggest that IL-1β 
antagonism may be a promising treatment for DMT2. 
Finally, Dr. Tschopp presented an interesting eff ect of 
interferon-beta (IFN-β) on inhibition of NALP3 signaling 
in multiple sclerosis.
Cofactor-specifi c regulation of NF-κB-dependent gene 
expression
Michael Hottiger, Zurich, Switzerland
Dr. Hottiger discussed mechanisms underlying NF-κB 
activity and emphasized the eff ect of cofactors on regu-
lation of NF-κB-dependent gene expression. Th e NF-κB 
family consists of fi ve complexes that have an important 
function in regulating immune and infl ammatory res-
ponses, apoptosis, cell proliferation, diff erentiation, and 
tumorigenesis. NF-κB-specifi c activity depends on the 
preferential recruitment and localization of NF-κB homo-
dimers/heterodimers, on the interaction with chromatin 
that enables its either constitutive and immediate or 
regulated and late accessibility, and on the combination 
of cofactors and post-translational modifi cation of NF-κB 
dimers.
Dr. Hottiger showed that the p65 subunit of NF-κB is 
acetylated in vitro and in vivo at three diff erent lysines – 
K310, K314, and K315 – by the histone acetyltransferase 
p300. Although general transcriptional activity of RelA/
p65 was not aff ected, there are specifi c sets of genes that 
were upregulated or downregulated by lysine-specifi c 
RelA/p65 acetylation. SIRT-2 interacts with p65 in cyto-
plasm and contributes to NF-κB-dependent gene expres-
sion via deacetylation of lysine K310. Poly (ADP-ribose) 
poly merase-1 (PARP-1) can also act as a promoter-
specifi c coactivator of NF-κB. Th e eff ect of PARP-1 is 
indepen dent of its enzymatic activity but its direct 
interaction with both subunits of NF-κB is required for 
its co activator function. Moreover, it was shown that 
acety lation of PARP-1 at specifi c lysine residues mediated 
by p300/CREB-binding protein is necessary for the 
above mentioned interaction of PARP-1 with NF-κB and 
coactivation of NF-κB by p300. CARM1 (coactivator-
asso ciated arginine methyltransferase) is another trans-
crip tional coactivator of NF-κB. CARM1 forms a 
complex with p300 and NF-κB (interacts directly with the 
NF-κB subunit p65) and thus, together with the trans-
criptional coactivators p300/CREB-binding protein, 
regu lates a subset of NF-κB-dependent genes. PRMT1 
(protein arginine methyltransferase 1) synergistically co-
activates NF-κB-dependent gene expression in a complex 
with the transcriptional coactivators p300/CREB-binding 
protein, CARM1, and PARP1. In the fi nal part of the talk, 
Dr. Hottiger presented the data on a mouse model of 
enterocolitis induced by Salmonella typhimurium and 
showed that PARP1 is expressed in the proliferative zone 
of cecum crypts, where it is required for the effi  cient 
expression of proinfl ammatory genes. In conclusion, 
cooperation between cofactors p300, PARP1, CARM1, 
and PRMT1 regulates NF-κB-dependent gene activation 
in vivo.
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Modulation of the immune response by exosomes
Paul Robbins, Pittsburgh, PA, USA
In the introduction to his talk, Dr. Robbins described 
exosomes as nanovesicles (40 to 100 nm) generated by 
diff erent cell types: reticulocytes, immune cells, platelets, 
epithelial cells, tumor cells, and so on. Exosomes contain 
antigen-presenting molecules MHC (major histo com-
pati bility complex) I and MHC II and adhesion, regula-
tory, and costimulatory molecules and nucleic acids, 
including miRNAs.
Dr. Robbins demonstrated that exosomes derived from 
dendritic cells (DCs) treated with immunomodulatory 
cytokines (IL-10 and IL-4) inhibit infl ammation in a 
murine model of delayed-type hypersensitivity (DTH). 
Moreover, systemic administration of exosomes derived 
from IL-10-treated DCs is able to suppress the onset of 
murine collagen-induced arthritis (CIA) as well as to 
reduce the severity of established arthritis.
Th e ability of the modifi ed DCs expressing IL-4 and 
exosomes derived from these DCs to suppress the DTH 
response is MHC class II- and Fas-ligand/Fas-dependent. 
Costimulatory molecules, such as B7-1/2 and PD-L1/2, 
play an important role in the function of antigen-present-
ing cells (APCs). Lack of B7-1 or B7-2 on DCs results in a 
loss of the ability of IL-10-treated DCs and their exosomes 
to suppress the DTH response, whereas IL-10-treated DCs 
expressing no PD-L1/2, as well as their secreted exosomes, 
have no ability to suppress DTH responses. Th us, B7-1 and 
B7-2, but not PD-L1 and PD-L2, on IL-10-treated DCs and 
derived exosomes are required for immunosuppressive 
functions of both DCs and exosomes.
As mentioned above, exosomes released by APCs 
express MHC, adhesion, and costimulatory molecules 
and may function as antigen-presenting particles. It was 
presented that exosomes fi rst bind to the APC surface 
and then are internalized by DCs. Th us, these inter-
nalized exosomes can be subsequently processed by DCs 
for presentation to T cells. Dr. Robbins showed that 
exosomes derived directly from plasma are immuno-
suppressive. Th e anti-infl ammatory eff ect of plasma-
derived exosomes in immunized mice was mediated by 
exosomes containing MHC II, FasL, and CD11b. More-
over, TNFα was shown to be bound on the membrane of 
exosomes derived from mouse models of CIA and from 
plasma of patients with RA. Th erefore, there is a question 
of exosomes as a biomarker of the disease.
In conclusion, the immunosuppressive eff ect of exo-
somes is dependent on the presence of MHC II, FasL, and 
B7-1 and B7-2, and exosomes may be internalized by 
APCs. Th us, APC-derived exosomes could be used 
therapeutically for the treatment of autoimmune disease 
and infl ammatory disorders. However, further experi-
ments are needed to elucidate in detail the structure, 
mechanism of action, and clinical application of exosomes.
Session 3: Molecular immunology
Chairs: Peter E Lipsky, Bethesda, MD, USA, 
and Sandra Sacre, Brighton, UK
Session 3 summarized by Hossein Hemmatazad
Human Th-17 in infection and immunity
Antonio Lanzavecchia, Bellinzona, Switzerland
Lanzavecchia started his presentation by describing the 
role of Th -17 cells in inducing experimental auto-
immune encephalomyelitis (EAE). He showed that mice 
lacking CCR6, a chemokine receptor characteristic of 
Th -17 cells, are resistant to the induction of EAE. CCR6 
binds to its ligand, CCL20, in choroid plexus and 
controls immune surveillance of the central nervous 
system. Next, he discussed the diff erentiation of Th -17 
cells in humans and mice. In mice, the diff erentiation of 
Th -17 cells requires transforming growth factor-beta 
(TGF-β) and IL-6, where as in humans IL-1β and IL-6 
are needed. In humans, in contrast to mice, TGF-β has 
inhibitory eff ects on Th -17 diff erentiation. Lanzavecchia 
explained that in mice IL-22 has been considered a 
typical Th -17 cytokine and is made by fully diff er-
entiated Th -17 cells. It has been linked to skin homeo-
stasis and infl ammation. Of interest, in humans, most of 
the IL-22-producing cells do not make IL-17. Th e 
diff erentiation of T cells producing only IL-22 is effi  ci-
ently induced in naive T cells by plasma cytoid DCs in 
an IL-6- and TNF-dependent way. Lanza vec chia and 
colleagues are developing high-throughput methods to 
analyze the human memory responses. Th e idea is that 
analyzing the repertoire of B cells, plasma cells, and 
memory T cells may allow us to isolate mono clonal 
antibodies and T-cell clones to identify target antigens 
and the specifi c class of response. Finally, he showed 
that Candida albicans and Staphylococcus aureus both 
induce Th -17 diff erentiation, but in diff erent ways. C. 
albicans induces Th -17 diff erentiation in an IL-1β-
dependent way. IL-1β shuts off  IL-10 production, so 
cells make IL-17 but not IL-10. In contrast, S. aureus 
can induce Th -17 diff erentiation in an IL-1β-inde-
pendent manner. In this case, IL-10 production is 
retained, so these cells have less potential to induce 
infl ammation.
Break of immunotolerance
Iain McInnes, Glasgow, UK
McInnes started his talk by addressing the importance of 
adaptive immunity in the pathogenesis of RA. He 
explained how diffi  cult it is to observe the breach of 
endogenous tolerance in an animal model, because these 
models rely on aggressive and artifi cial self-antigen 
immuni zation and this does not allow us to assess the 
very early breach of immunotolerance. A new approach 
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is to look at DC behavior and their phenotype in RA, 
and the idea is to set up an in vivo model system that 
can be analyzed in real time. McInnes and colleagues 
took DCs and loaded them up with selected antigens 
(collagen type II whole protein) to generate a collagen-
induced mouse model of arthritis. By analyzing the 
interactions between DCs and T cells in this in vivo 
model, they could demon strate conventional DC (cDC) 
activation and antigen presentation associated with 
breach of self-tolerance, an ability of these cells to 
transfer autoimmunity, together with a central role for 
cDCs in the TNFα-dependent development of self-
reactivity and RA pathogenesis. Furthermore, he 
showed some data on the eff ect of abatacept to limit the 
breach of self-tolerance via eff ects on the generation of 
T follicular helper cells. Abatacept prevented the 
emergence of self-reactivity and has potential usefulness 
in early infl ammatory arthropathies associated with 
autoantibody expression.
The tumoricidal activity of interleukin-12 is mediated via 
lymphoid tissue-inducer cells
Burkhard Becher, Zurich, Switzerland
In a wonderful talk, Becher presented his data on IL-12-
mediated repression of subcutaneous melanoma. Th ere 
are many cytokines used in cancer immunotherapy, 
such as IFN-α, IL-2, and IL-12. To determine the 
mechanisms by which IL-12 mobilizes antitumor 
immunity, Becher and his group generated B16.F10 
mouse melanoma cell lines that continuously release a 
fusion protein of IL-12. Th ey could show that IL-12 
signifi cantly reduced tumor growth in wild-type mice 
whereas in IL12rb2−/− mice, which lack the IL-12-
specifi c receptor subunit, melanoma cells showed no 
reduction in growth. But how does IL-12 repress 
cancer? To answer this question, they did a systemic 
analysis of the IL-12-induced immune responses and 
demonstrated that tumoricidal activity of IL-12 is 
independent of adaptive immunity, lymphocytes, or 
circulating natural killer cells. By excluding a series of 
cell types, which were candidates for IL-12-mediated 
anti tumor response, they observed that IL-12-
responsive tumor-invading cells are in fact an innate, 
lineage-negative leukocyte belonging to a subset of 
lymphoid tissue-inducer (LTi) cells expressing the 
natural cyto toxicity receptor NKp46. Th ese LTi cells 
also produce IL-22 and IL-17, but of interest, the IL-12-
mediated melanoma repression seemed to be indepen-
dent of these eff ector cytokines. IL-12-stimulated 
NKp46+ LTi cells alter tumor microvasculature and this 
leads to up regulation of adhesion molecules (such as 
vascular cell adhesion molecule) and subsequent tumor 
control.
Session 4: Cellular autoimmunity
Chairs: Jean-Michel Dayer, Geneva, Switzerland, 
and Temy Mok, Hong Kong, China
Session 4 summarized by Emmanuel Karouzakis
Cytokine networking
Eddie Liew, Glasgow, UK
Dr. Liew presented data on the function of IL-33 cytokine 
in sepsis and osteoclast diff erentiation. IL-33 is secreted 
during tissue injury by a variety of cell types. Th e receptor 
of IL-33 consists of ST2 and IL-1 receptor accessory 
protein (IL-1RAP) that is expressed on Th -2 cells and 
mast cells. Th e evolutionary role of IL-33 is to prevent 
the establishment of infection. Administration of IL-33 
prevents nematode infection, Coxsackie virus infections, 
artherosclerosis, and asthma and attenuates sepsis. Also, 
IL-33 can induce allergic anaphylaxis and is associated 
with central nervous system diseases such as Alzheimer’s 
disease. Dr. Liew focused his presen tation on the role of 
IL-33 in sepsis and neutrophil migration on the site of 
infection. His group could demonstrate that the ST2 
knockout mouse during cecal ligation and puncture is 
more susceptible to sepsis than the wild-type mouse. 
Further more, IL-33 improves the neutrophil migration 
on the site of infection and prevents downregulation of 
CXCR2 in neutrophils during sepsis. IL-33 allows the 
persistent expression of CXCR2 in neutrophils by 
blocking the activity of GSK2. Dr. Liew claimed that 
IL-33 is important in human sepsis. IL-33 induces the 
migration of human neutrophils during infl ammation. 
Interestingly, sepsis non-survivors have less CXCR2 in 
their peripheral blood neutrophils than sepsis survivors. 
Finally, he showed that the soluble ST2 is highly ex-
pressed in the serum of non-survivors of sepsis. His talk 
concluded on the role of IL-33 osteoclast diff erentiation. 
IL-33 is expressed in the joints of TNFα transgenic mice. 
IL-33 reduces bone erosion and osteoclast formation in 
TNFα transgenic mice. Th e expression of TRAP, NFAT, 
and cathepsin K is reduced after IL-33 treatment. ST2 
knockout mice have more bone erosion than wild-type 
mice. In addition, IL-33 increases the number of macro-
phages, DCs, and neutrophils in the spleen of the mice. 
Interestingly, IL-33 inhibits osteoclast diff erentiation and 
promotes the development of MT2 macrophages.
Genome-wide association studies for rheumatoid arthritis
Lars Klareskog, Stockholm, Sweden
Dr. Klareskog analyzed the diff erent genetic and environ-
mental interactions of antibodies to citrullinated protein 
antigen (ANCA)-positive individuals as a risk factor for 
RA. Diff erent studies in RA have shown that there is a 
genetic risk for RA. Th e most important susceptibility 
genes are PTPN2 and HLADR shared epitope (SE). New 
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genome-wide genetic studies have shown that HLADR 
SE and PTPN2 are more frequent in ANCA-positive 
cases than ANCA-negative RA cases. Dr. Klareskog 
emphasized that environmental exposure such as smok-
ing can have a great impact on the genetic infl uence of 
RA. Environmental-gene interaction studies have shown 
that there is a great risk of RA if you are a smoker and 
HLADR SE-positive. Other studies have analyzed gene-
to-gene interaction. Th ese studies have determined that 
the PTPN2 susceptibility gene, together with HLADR SE 
and smoking, increases the risk for RA. Dr. Klareskog 
created a model for smoking and HLADR SE genes which 
could be tested in the laboratory. Chronic exposure of 
lungs to smoking increases the activation of the peptidyl-
arginine deiminase enzymes that cause the citrullination 
of diff erent proteins in the lung. APCs (macrophages and 
DCs) that have the SE motif may bind to some of these 
citrullinated proteins and trigger an immune response. 
Activated T cells are generated and interact with B cells. 
In turn, the activated B cells produce ANCA antibodies 
that are present very early in RA. Synovial infl ammation 
in the joint can citrullinate synovial antigens that form 
complexes with ANCA and bind to the Fc receptors of 
synovial macro phages. His talk concluded that geneticists 
should separate patients with RA into two diff erent 
subsets and functional immune system studies should be 
performed in specifi c T-cell subsets with a specifi c 
genetic and environmental background.
Dynamic regulation of chemokines and their receptors
Mario Mellado, Madrid, Spain
Dr. Mellado described a dynamic model between the 
chemokine receptors CXCR1 and CXCR2 with their 
ligand CXCL8. Chemokines are signifi cant for lympho-
cyte traffi  cking to the site of injury. Th ey are a large 
family of small proteins that signal to a G protein-like 
receptor. A chemokine can activate diff erent chemo kine 
receptors, and immune cells express diff erent chemo kine 
receptors, depending on the activation stage or tissue 
localization. Chemokines are associated with diff erent 
diseases (RA, asthma, AIDS, and cancer). A better under-
standing of chemokine oligomerization is needed in 
order to identify new antagonists. Dr. Mellado studied 
the dimeri zation of chemokine receptors by using a 
biophysical technique called fl uorescence resonance 
energy transfer. A specifi c chemokine receptor confor-
ma tion in the cell membrane can have diff erent func-
tional properties and activate diff erent signaling path-
ways. For example, heterodimers of CXCR2/CXCR5 play 
an important role in cell adhesion. His talk concluded 
with a model of chemokine receptor homodimer and 
heterodimer dynamics. CXCR1 and CXCR2 form an 
array of homodimers and heterodimers on the cell 
surface. During stimulation of cells with CXCL8/IL8 
ligand, there is a disruption of heterodimer formation. 
Homodimers are stabilized and there is high rate of 
CXCR2 internalization.
Session 5: Cell biology
Chairs: Robert Eisenberg, Philadelphia, PA, USA, 
and Rene Toes, Leiden, The Netherlands
Session 5 summarized by Fabienne Niederer
New lessons from animal models
Thomas Pap, Münster, Germany
Th omas Pap started the cell biology session by intro-
ducing the aggressive phenotype of RA synovial fi bro-
blasts (SFs). In an in vivo experiment, RA SFs, together 
with human cartilage, were implanted into severe 
combined immunodefi cient (SCID) mice. RA SFs showed 
an active movement to the naive cartilage, leading to a 
marked destruction of the cartilage. Interestingly, RA 
SFs, but not osteoarthritis (OA) SFs, were able to spread 
the disease in the SCID mice model. Next, he discussed 
inducible human tumor necrosis factor transgenic 
(hTNFtg) mice. Like the constitutive TNF transgenic 
mice, these mice show an RA-like arthritis, but allow the 
analysis of genes, the knockout of which is embryonically 
lethal in a TNFα infl ammatory background. By using 
these mice, Th omas Pap’s group wanted to address the 
question of whether pathogenic changes in RA are 
triggered and maintained by cartilage damage. Th ey 
observed that the loss of proteoglycans is an important 
prerequisite for the attachment of SFs to cartilage in 
hTNFtg mice. Th is attachment was mediated by integrins, 
as confi rmed by the fact that loss of α1β2 integrin reduced 
cartilage destruc tion not only in vitro but also in hTNFtg 
mice. In addition, the loss of other proteoglycan-sensing 
mole cules, such as syndecan 4, protected mice from 
cartilage damage in the hTNFtg mice model of RA. 
Furthermore, this protection was linked to reduced 
production of matrix-metalloproteinase 3. Pap and his 
group observed the upregulation of syndecan 4 in RA SFs 
and in hTNFtg mice and hypothesized that syndecan 4 
not only is required for SF attachment but also modulates 
cytokine signaling in SFs by binding the key RA cytokine 
IL-1.
Molecular biology of aging
Trygve Tollefsbol, Birmingham, AL, USA
In his talk, Tollefsbol pointed out the trade-off  between a 
person’s dream to stay young and the continuous need for 
CR. Nowadays, the intake of 25% to 40% less calories, 
including all needed nutrients, was shown to be the best 
way to stay young, as CR promoted longevity not only in 
yeasts and mice but also in non-human primates. Th is 
fi nding was nicely illustrated by pictures from 
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calorie-restricted, young-looking (but incredible hungry) 
primates.
Tollefsbol connected this eff ect with the molecular 
clock of aging. Telomere shortening was shown to 
correlate with the age of a cell. Moreover, telomerase was 
found to be activated in cancer cells. Th e group of 
Tollefsbol wondered whether in vitro sugar reduction 
could help answer questions about human CR and aging. 
Indeed, glucose restriction extended the lifespan in a 
human embryonic fi broblast cell line (WI-38) and, more-
over, induced apoptosis in a precancerous human cell line 
(WI-38/S). Levels of hTERT, the gene for telomerase 
reverse transcriptase, were found to be induced and the 
tumor-suppressor protein p16 to be reduced after 2 to 
4  weeks of glucose restriction in the normal cell line 
(WI-38). In the precancerous cell line (WI-38/S) the 
eff ects were the reverse and lower levels of hTERT and 
higher levels of p16 were detected. Furthermore, glucose 
restriction was shown to result in chromatin remodeling 
of the promoters of the hTERT and p16 genes. In 
conclusion, this presentation clearly showed that glucose 
restriction mediates its eff ects by epigenetic regulation 
via hTERT and p16, thereby extending the cellular 
lifespan of normal cells or mediating cellular senescence 
by induction of apoptosis in precancerous cells.
Tissue repair with stem cells
Rocky S Tuan, Pittsburgh, PA, USA
Tuan started his presentation by listing diff erent 
treatment options for degenerative joint diseases, such as 
total joint arthroplasty, non-steroidal anti-infl ammatory 
drugs, chondrocyte implantation, and cartilage trans-
plantation, and fi nally put an emphasis on regenerative 
surgery methods. Tuan wanted to apply principles of 
engineering and life sciences to the regeneration of tissue 
and cell organs. To address this topic, he worked with 
human mesenchymal stem cells (hMSCs). Th ese cells 
were shown to form cartilage upon TGF-β. To scale up a 
little piece of cartilage became a big challenge. Tuan pre-
pared a three-dimen sional scaff old made out of nano-
fi bers by using electro spinning processes. He fi nally 
succeeded in getting cartilage pieces with diameters 
ranging from 1.5 to 4 cm. Next, Tuan’s working group 
wanted to bring them into animals. Owing to the (now) 
big size of the cartilage pieces, big animals (for example, 
pigs) were needed. Th e aim of the following in vivo 
experiments was to repair iatrogenic cartilage defects. 
Tuan showed that nano fi brous scaff olds seeded with 
hMSCs eff ectively repaired cartilage defects in a swine 
model. Furthermore, Tuan proposed that, by regulating 
the stem cell niche, hMSCs should be able to diff erentiate 
into osteoblasts, chondro cytes, and adipocytes and 
thereby lead to the desired plasticity of the joint. In a 
search for genes downregulated in diff erentiated cells and 
upregulated in undiff erentiated cells, they found IL-6 as a 
candidate stemness gene to maintain the proliferative 
and undiff erentiated state of hMSC stemness, an impor-
tant parameter for the optimization of manipulation of 
hMSCs.
Session 6: Updates in rheumatology
Chairs: Tsutomu Takeuchi, Tokyo, Japan, 
and Jesús Salvador, Madrid, Spain
Session 6 summarized by Kerstin Klein
Novel pain targets
Hanns-Ulrich Zeilhofer, Zurich, Switzerland
In his talk, Hanns-Ulrich Zeilhofer presented three novel 
promising targets for the treatment of chronic pain: (a) 
the transient receptor potential cation channel subfamily 
V member 1 (TRPV1), (b) Na+ channels (Nav1.7 and 
Nav1.8), and (c) the nerve growth factor (NGF). TRPV1 
was originally identifi ed as a receptor for capsaicin, the 
main pungent ingredient in hot chili peppers. TRPV1 
channels are activated upon noxious heat and mechanical 
damage. TRPV1−/− mice were still responsive to noxious 
heat but were insensitive to infl ammatory hyperalgesia. 
Clinical studies for TRPV1 antagonists were promising. 
However, the main side eff ect in treated patients was 
hyperthermia.
Na+ channels are established targets for local analgetics 
and lately have also been in discussion as targets for the 
treatment of chronic pain. Th e SCN9A gene, encoding for 
Nav1.7, has been associated with diverse Na+ channelo-
pathies. An SCN9A mutation, prevalent in Pakistani 
families and leading to a premature stop codon, led to pain 
insensitivity of the aff ected individuals. Furthermore, gain-
of-function mutations of the SCN9A gene cause two 
diff erent diseases. In patients with erythro melalgia, Nav1.7 
is activated at lower potentials, whereas in patients with 
paramyxal extreme pain disorder, Nav1.7 channel 
activation is extremely prolonged.
Another group of promising drugs for the treatment of 
chronic pain consists of antagonists of the neurotrophin 
NGF. NGF binding to its high-affi  nity receptor tyrosine 
kinase receptor A (TrkA) in the dorsal root ganglion 
induces a signal cascade that results in the release of 
calcitonin gene-related peptide, substance P, and brain-
derived neurotrophic factor. Beside nerves, cells such as 
keratinocytes express NGF. During infl ammation, mast 
cells and macrophages serve as additional sources of 
NGF. Pfi zer Inc (New York, NY, USA) has developed a 
monoclonal antibody (tanezumab) against NGF. Clinical 
trials for the treatment of knee pain due to OA have been 
stopped recently. However, clinical trials for other pain 
conditions are ongoing. Since the treatment of large 
groups of patients with monoclonal antibodies is costly, a 
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vaccination against NGF (NGF-Qβ) was developed in 
Zeilhofer’s lab. Vaccinated mice in a model of infl am ma-
tory pain recovered faster than control animals. Further-
more, vaccination reduced thermal hyperalgesia in a 
mouse model of CIA. Side eff ects on peptidergic sensory 
nerve fi bers were not observed. Furthermore, no un-
desired eff ects concerning the inte grity of the blood-
brain barrier were found.
Better understanding the hidden face of osteoarthritis
Jean-Pierre Pelletier, Montreal, QC, Canada
In his talk, Jean-Pierre Pelletier pointed out the necessity 
of the development of disease-modifying drugs for the 
treatment of OA (DMOADs). So far, no DMOADs have 
been approved by the US Food and Drug Administration, 
and current therapies for OA are directed toward con-
trol ling symptoms, maintaining function, and reducing 
further joint damage. A challenging issue in the develop-
ment of DMOADs is the design of clinical trials. First of 
all, a careful selection of patients is important since age, 
gender, body mass index, and other factors have been 
reported to have an impact on study outcome. So far, no 
clear guidelines for inclusion criteria for patients exist. 
Other important aspects are the method of determination 
of disease progression and the selection of target joints. 
So far, the evaluation of symptoms in DMOAD trials is 
the same as in short-term trials. Pelletier suggested 
focusing on the global evaluation of structural changes in 
several joints instead of measuring a reduction of pain on 
the visual analogue scale. Furthermore, he recommended 
the use of quantitative magnetic resonance imaging 
(qMRI) instead of x-ray technology for the measurement 
of structural changes in the joints. In 2009, Raynauld and 
colleagues published the fi rst multicenter clinical trial 
study using qMRI (Raynauld JP et al., Ann Rheum Dis, 
2009). Pelletier advised the recording of total joint 
replacements after 6 years of follow-up; these data, which 
would serve as an adequate readout for DMOAD trials, 
can be easily collected by means of questionnaires. So far, 
no international guidelines for DMOAD clinical trials 
exist.
Do regulatory T cells control the switch from acute to 
chronic arthritis?
Thomas Kamradt, Jena, Germany
In his presentation, Th omas Kamradt pointed out the 
role of regulatory T cells (Tregs) in the switch from acute 
to chronic infl ammatory diseases. Tregs are CD25+CD4+ 
T cells that express the transcription factor FoxP3. Th ey 
are generated in the thymus as well as in the periphery 
from naive T cells. Th e exact mechanism of Treg action is 
unclear. An increased number of Tregs was described in 
patients with arthritis. On the other hand, in mouse 
models of CIA and antigen-induced arthritis, Tregs were 
shown to delay the onset and downregulate the severity 
of the disease. Hence, Tregs have no eff ects in models of 
prostaglandine-induced arthritis. Kamradt reported that 
immunization of genetically unaltered mice with the 
ubiquitously expressed glycolytic enzyme glucose-6-
phosphate isomerase (G6PI) induced arthritis within 9 
days. Th is was a T cell-dependent disease since depletion 
of CD4+ cells prevented and cured G6PI-induced 
arthritis. G6PI-induced arthritis was monophasic and 
self-limiting. Induction of a second round of arthritis by 
repeated G6PI immunization failed. However, transient 
depletion of CD25+ cells increased the number of G6PI-
activatd CD4+CD154+ Th  cells and caused chronic 
arthritis. Th ese CD4+CD154+ Th  cells were polyfunctional 
since they were capable of producing up to fi ve cytokines 
in parallel upon CD25+ cell depletion. Th e mechanism of 
how an early and transient depletion of Tregs results in 
chronic destructive arthritis remains to be determined. 
Kamradt suggested the possibility that newly evolving 
Tregs in late arthritis are insuffi  cient. Alternatively, an 
early instruction of eff ector cells by dysregulated T cells 
is possible. Furthermore, direct interaction of Tregs with 
eff ector cells might be possible. Polyfunctional T cells 
might also be relevant in autoimmunity in patients, and 
Tregs might play an important role in the preclinical 
phase of arthritis.
Novel epigenetic strategies for autoimmune disease and 
cancer
Wesley Brooks, Tampa, FL, USA
Wesley Brooks pointed out the role of the loss of epi-
genetic control in the development of autoimmune 
diseases. Th e female predominance of diseases such as 
mul tiple sclerosis, RA, lupus erythematosus, and Sjörgren 
syndrome suggests the involvement of hormones, X 
chromosomes, and the X-chromosomal inactivation 
process. Early in embryogenesis, the second X chromo-
some in female cells undergoes inactivation in order to 
achieve dosage compensation. Approximately 85% of the 
genes on the inactivated X chromosome (Xi) undergo 
inactivation. Owing to its perinuclear localization, the 
late replication, hypermethylation, and the limited access 
for DNA repair, the Xi is especially vulnerable to DNA 
damage. DNA mutations could interfere with the X 
inactivation process and then could become reactivated 
in daughter cells, resulting in a loss of epigenetic control. 
An interesting region on the short arm of the X 
chromosome is Xp22.1, which encodes for enzymes 
involved in the polyamine synthesis (namely spermine 
synthase and spermine/spermidine N1-acetyltransferase). 
Many agents, including estrogens, UV light, and viral 
infections, can induce polyamine synthesis. Increased 
polyamine synthesis could impact chromatin methylation 
and epigenetic control because of the increased needs for 
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S-adenosylmethionine, which is also used as a substrate 
for DNA methylation. Furthermore, polyamines can 
stabilize Z-DNA and alter gene transcription. Abnormal 
RNA polymerase III activity and overexpression of 
pseudogenes, such as Alu and LINE L1 sequences, have 
been described. Brooks suggested the enzymes ornithine 
decarboxylase and spermine/spermidine N1-acetyl-
transferase as suitable new targets for drug discovery.
ASIA: a new syndrome of autoimmune diseases induced by 
adjuvants
Yehuda Shoenfeld, Tal-Hashomer, Israel
In his presentation, Yehuda Shoenfeld discussed an auto-
immune disease called ‘autoimmune syndrome induced 
by adjuvant’ (ASIA). Autoimmune diseases have multi-
factorial causes, such as genetic predisposition, immuno-
defi ciency, hormones, and environmental factors, includ-
ing adjuvants. Adjuvants, the foremost of which is 
aluminum, are widely used in vaccines to stimulate the 
immune system. Although Shoenfeld did not want to 
doubt the benefi cial eff ects of vaccines, he referred to 
numerous studies and case reports documenting that 
vaccination of naive subjects can lead to autoimmunity. 
Causal relationships between diphtheria-tetanus-pertussis 
vaccination and measles-mumps-rubella (MMR) vaccina-
tion with arthritis have been described. Furthermore, a 
link between MMR and autoimmune thrombocytopenia 
has been reported. Whereas early adverse events of 
vaccinations (for example, fever or local reactions at the 
site of injection) are easily documented, the major 
diffi  culty of diagnosing ASIA is the lack of temporal 
association between the vaccination and the incidence of 
symptoms, and this lack is due to long latency periods. 
Moreover, the criteria for causality are not well defi ned, 
and unlike effi  cacy, safety cannot be measured directly. 
Animal models can be useful for studying the 
interrelation between vaccination and autoimmune 
phenomena.
Some vaccinations use silicone as an adjuvant. Th e 
wide use of silicone in breast operations led to many 
symptomatic cases of autoimmune disease. In some 
cases, the removal of silicone was suffi  cient for recovery 
of the patients. Shoenfeld concluded that the association 
between vaccination and autoimmunity raises many 
clinical, methodological, and ethical questions and that 
there is a need for increasing vaccine safety and 
identifying possible risk factors for the incidence of 
ASIA.
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